CD274 and non-small cell lung carcinoma: Two PD-1 inhibitors (Nivolumab and Pembrolizumab) and one PD-L1 inhibitor (atezolizumab) have been approved by FDA and EMA for 2nd line treatment in NSCLC and Pembrolizumab for first line treatment in patients whose tumors have high expression of PD-L1 (>50%).